top of page

"Antibiotic resistance is one of the biggest threat to global health today. It can affect anyone, of any age, in any country."


Cūrza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases.


Cūrza's goal is to develop novel classes of antibiotics that combat the rising epidemic of antibiotic resistance that now contributes to the death of 5,000,000 people each year.


Cūrza is always looking for top tier talent. For all job inquires, please send a copy of your resume.

How are we protecting our world?

Petri Dish


Our lead program, CZ-02 is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens, with a focus on drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. learn more

Ribosomal Antibiotics

In this program, our focus is on developing novel antibiotics for ESKAPE pathogens or “superbugs”. We have designed two novel classes of antibiotics that show both selectivity and potent activity against many of the ESKAPE pathogens. learn more


Antibiofilm Antibiotics

Biofilms can also cause severe infections in our bodies. Tuberculosis, diabetic ulcers, Lyme disease, medical device-related infections, osteomyelitis, chronic skin wounds and infections that accompany cystic fibrosis are all examples of biofilm-related infections. learn more

We want to hear from you

Thanks for submitting!

650 Komas Drive, Suite 202

Salt Lake City, UT 84108

bottom of page